Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry
Authors:
- 4 October 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (44) , 4715-4718
Abstract
Sex-differences in characteristics and outcome in heart failure with preserved ejection fraction (HFpEF) have been well documented.1,2 However, whether these differences vary by left ventricular ejection fraction (LVEF) are unclear. A recent study showed substantial differences in morphological and hemodynamic characteristics in HFpEF patients with high-normal (>60%) vs. low-normal (50%–60%) LVEF, which might partly explain their heterogeneous responses to pharmacotherapy.3 Post-hoc analyses of clinical trials suggest that the benefits of neurohormonal modulators extended to a higher range of LVEF in women than in men.4,5 It is therefore important to compare clinical characteristics and outcomes between male and female HFpEF patients by LVEF. Additionally, recent epidemiologic studies reported a new phenotype characterized by supranormal LVEF (LVsnEF);6,7 whether there are sex differences in LVsnEF deserves further investigation. The China Cardiovascular Association (CCA) Database-Heart Failure (HF) Center Registry is a nationwide multicentre study, which was approved by the Central Ethics Committee of Beijing Hospital (2018BJYYEC-059-02).8 All secondary and tertiary hospitals from mainland China are welcome to participate in the registry, and no additional specific selection criteria are required. Between January 2017 and December 2021, 575 CCA Database-HF Center-certified secondary and tertiary hospitals across the 31 provinces of mainland China participated in the registry. Hospitalized patients with a principal discharge diagnosis of HF were eligible for the registry, and those who died during index hospitalization were excluded. Diagnostic criteria of HF are based on the guidelines,9,10 including presence of clinical symptoms/signs of HF, cardiac structural and/or functional abnormality on echocardiogram, and elevated serum natriuretic peptide level. If LVEF was ≥50% as measured by echocardiography at index hospitalization, HF was defined as HFpEF.9,10 Among the overall HFpEF patients recruited (n = 125 208), after excluding those who were lost to follow-up (n = 8321), had n = 65 151), or lacked sex data (n = 25), 51 711 hospitalized HFpEF patients were included. Data from electronic and/or physical health records were collected and entered into an online central database by trained staff. Study variables collected included demographics, anthropometrics, education, vital signs at admission, HF characteristics [precipitating factors for index HF admission, hospitalization for HF (HHF) in the previous 12 months, clinical symptoms/signs, New York Heart Association (NYHA) class], laboratory and echocardiography data, comorbidities [smoking status, alcohol consumption, hypertension, diabetes mellitus, dyslipidaemia, obesity, chronic kidney disease (CKD), atrial fibrillation (AF), coronary heart disease (CHD), prior myocardial infarction, prior stroke/transient ischaemic attack, peripheral arterial disease, chronic obstructive pulmonary disease (COPD), anaemia, thyroid dysfunction, obstructive sleep apnoea, anxiety/depression, and cancer], prior intervention and device therapy, and medications prescribed at discharge. After discharge, patients were followed by trained physicians during an outpatient visit or via a telephone interview during the first week (±1 week), the first month (±14 days), the third month (±30 days), and the first year (±90 days). The primary outcome was a composite of HHF or cardiovascular death. Follow-up duration was calculated from the date of discharge until the occurrence of the first event (HHF or cardiovascular death) or at the end of 1-year follow-up if no event occurred. All-cause death and all-cause hospitalization were evaluated as secondary outcomes. All events were reported by the participants or their immediate relatives without adjudication.Keywords
This publication has 9 references indexed in Scilit:
- Clinical characteristics and 1‐year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database‐Heart Failure Center RegistryEuropean Journal of Heart Failure, 2022
- Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection FractionCirculation, 2022
- Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failureEuropean Journal of Heart Failure, 2022
- Interactions Between Left Ventricular Ejection Fraction, Sex and Effect of Neurohumoral Modulators in Heart FailureEuropean Journal of Heart Failure, 2020
- Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection FractionCirculation, 2020
- Sex differences in heart failureEuropean Heart Journal, 2019
- Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?European Heart Journal, 2019
- Sex Differences in Cardiovascular PathophysiologyCirculation, 2018
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016